Skip to content

PolitiKit

Lobbying by AstraZeneca Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

AstraZeneca Canada

Meetings this Parliament
0
With MPs
0
Since Nov 2021
1
Active registrations
1

Most recent reported meeting: Feb 1, 2023.

Registrations in effect

Consultant In effect since Mar 27, 2026

Consultant William Dempster of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (13)
  • Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
  • Public Health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
  • Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
  • Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
  • Federally-funded public drug plans, including the Non-Insured Health Benefits Program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
  • Establish accountability with Health Canada, Canada's Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
  • Engage with Canadian government officials to discuss and provide input on Canada's countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
  • Engagement with the government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
  • Canada’s Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
  • Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
  • Annual federal Budgets and Budget updates relating to the biopharmaceutical industry

Registration 778465-373803-3. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by William Dempster · Consultant

    • Ben Chin · Senior Advisor, Prime Minister's Office (PMO)
    • Daniel Saad · Senior Policy Advisor, Prime Minister's Office (PMO)
    • Udita Samuel · Ontario Regional Advisor, Prime Minister's Office (PMO)
    • Mark Katchuck · Special Assistant, Prime Minister's Office (PMO)

    Economic DevelopmentHealthResearch and DevelopmentScience and Technology

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.